Animal models of allergic bronchopulmonary aspergillosis

被引:0
作者
Viswanath P. Kurup
Gabriele Grunig
机构
[1] Medical College of Wisconsin and the Research Service,Allergy
[2] V A Medical Center,Immunology Division
[3] Columbia University of Physicians and Surgeons and St. Luke's-Roosevelt Hospital,Department of Pathology
来源
Mycopathologia | 2002年 / 153卷
关键词
allergic bronchopulmonary aspergillosis; murine model; cytokines; chemokines; knockout mice; immunotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
Among the allergic fungi, Aspergillus fumigatus, a saprophytic mold, distributed widely in the environment is a frequently recognized etiologic agent in a number of allergic conditions. Among the different allergic diseases caused by this fungus, allergic bronchopulmonary aspergillosis (ABPA) is by far the most significant one. The immunopathogenesis of this disease is not fully understood. Although several immunomodulatory treatments are available for allergic disease, none of them are applicable or relevant or useful in fungal induced allergy. It is essential to understand the pathogenesis of the disease including the antigen induced immunoregulation and the resulting factors, such as cytokine, chemokines, pathways activating factors, inflammatory and airway remodeling factors need to be understood for intervening with appropriate treatment. Animal models are essential in understanding these features of the disease. Several models of allergic aspergillosis have been developed in recent years in various animals. However, murine models have been studied more carefully and extensively. The exposure to antigen in mice leads to allergy very similar to ABPA with high IgE, elevated peripheral blood and lung eosinophils, pulmonary inflammation, and airway hyperreactivity. The role of various cytokines and chemokines and their receptors were also studied. In addition, immunotherapy and vaccination have been attempted in recent years using the murine model of ABPA. This review covers the murine model of Aspergillus induced allergy and asthma and presented critically our current understanding of the subject and the potential application of such a model in future for developing treatment modalities.
引用
收藏
页码:165 / 177
页数:12
相关论文
共 323 条
  • [1] Knutsen AP(1990)T-and B-cell dysregulation in cystic fibrosis patients with allergic bronchopulmonary aspergillosis Clin Immunol Immunopathol 55 129-138
  • [2] Mueller KR(2000)Selected recombinant Clin Exp Allergy 30 988-993
  • [3] Hutcheson PS(1986) allergens bind specifically to IgE in ABPA Arch Intern Med 146 916-918
  • [4] Slavin GR.(1984)Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenograpbic studies J Allergy Clin Immunol 73 44-48
  • [5] Kurup VP(1979)Allergic bronchopulmonary aspergillosis in cystic fibrosis Am Rev Respir Dis 120 863-873
  • [6] Banerjee B(1995)Aspergillosis and atopy in cystic fibrosis Ann Allergy Asthma Immunol 74 484-488
  • [7] IIeminann S(1998)Soluble serum interleukin 2 receptors in patients with asthma and allergic bronchopulmonary aspergillosis J Lab Clin Med 131 228-235
  • [8] Greenberger PA(1989)IgE downregulation and cytokine induction by J Lab Clin Med 113 428-435
  • [9] Blaser K(2000) antigens in human allergic bronchopulmonary aspergillosis Am J Path 156 723-732
  • [10] Craineri R.(1996) T cell responses in cystic fibrosis patients with allergic bronchopulmonary aspergillosis J Infect Dis 172 1554-1560